Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tuhura Biosciences Inc (HURA)

Tuhura Biosciences Inc (HURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,646
  • Shares Outstanding, K 63,579
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,680 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta -0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 1
  • High Estimate $-0.12
  • Low Estimate $-0.12
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3400 +5.22%
on 04/02/26
2.2500 -37.33%
on 03/17/26
-0.1100 (-7.24%)
since 03/02/26
3-Month
0.4100 +243.90%
on 02/03/26
2.2500 -37.33%
on 03/17/26
+0.6605 (+88.13%)
since 01/02/26
52-Week
0.4100 +243.90%
on 02/03/26
4.4400 -68.24%
on 04/21/25
-2.0700 (-59.48%)
since 04/02/25

Most Recent Stories

More News
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

TAMPA, Fla. , April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.4100 (-12.96%)
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology

KTRA : 0.2154 (-6.31%)
HURA : 1.4100 (-12.96%)
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TAMPA, Fla. , Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.4100 (-12.96%)
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TAMPA, Fla. , Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.4100 (-12.96%)
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AML

HURA : 1.4100 (-12.96%)
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

TAMPA, Fla. , Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.4100 (-12.96%)
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders

HURA : 1.4100 (-12.96%)
TuHURA Biosciences Provides Corporate Update Following Recent Financing

Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda ® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special...

HURA : 1.4100 (-12.96%)
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TAMPA, Fla. , Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.4100 (-12.96%)

Business Summary

TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA...

See More

Key Turning Points

3rd Resistance Point 1.8200
2nd Resistance Point 1.7100
1st Resistance Point 1.5600
Last Price 1.4100
1st Support Level 1.3000
2nd Support Level 1.1900
3rd Support Level 1.0400

See More

52-Week High 4.4400
Fibonacci 61.8% 2.9005
Fibonacci 50% 2.4250
Fibonacci 38.2% 1.9495
Last Price 1.4100
52-Week Low 0.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.